Spravato can be especially important for cost-conscious patients because it has established insurance authorization pathways that ordinary self-pay IV ketamine often does not.
Spravato is esketamine nasal spray. It is administered in a certified healthcare setting and patients are monitored after dosing. Insurance coverage is not automatic, but major carriers publish prior-authorization or medical-necessity pathways.
Ketamine Compass currently asks users to select Aetna, UnitedHealthcare/Optum, Cigna/Evernorth, Blue Cross Blue Shield, Humana, Medicare, Medicaid, another insurer, or no insurance. We use public carrier and provider information to prioritize potential insurance-compatible matches.
Carrier selection does not prove coverage. Exact benefits can depend on the member's plan, diagnosis, network status, prior authorization, deductible, copay, and coinsurance.
Aetna's current commercial medical policy requires precertification and lists medical-necessity criteria for Spravato. UnitedHealthcare and Cigna also maintain current commercial authorization policies. Aetna policy · UnitedHealthcare · Cigna
Answer 13 questions about insurance, budget, location, treatment preference, and care preferences. Ketamine Compass will rank relevant options from our provider dataset.
Show my matches